Guest guest Posted February 12, 2010 Report Posted February 12, 2010 re: However, I have not been able to get any follow-up on what the trial's demonstrated. This does not encourage participation in clinical trials. Amen! Pat. A notable quote on this subject: " ... the practice of publishing only some results, but not others,3,4 undermines our collective ability to make rational decisions about medical care. ... Ethical clinical research should contribute to generalizable knowledge and improve human health. **** The dedication of patients who take the risks to participate in clinical research is dishonored when their data remain secret. " SPECIAL REPORT: Progress and Deficiencies in Clinical Trial Reporting http://bit.ly/a9ffVv == However, I have not been able to get any follow-up on what the trial's demonstrated. This does not encourage participation in clinical trials. > > Pat > age 53, > dx 11/04; Rituxan monotherapy 9/05-11/07 > clonal evolution to 11q del; unmutated > FCR+Lumi 12/07 - 3/08 5 of 6 cycles - CR > Quote
Guest guest Posted February 12, 2010 Report Posted February 12, 2010 This is a critical issue - lets please have more facts - the trial was conducted, the patient achieved a CR, and now we have doubts? The lack of information, if that is indeed the case, could be alarming. Could some of you guys who know more about this please post? Thanks, In a message dated 2/12/2010 12:39:57 P.M. Eastern Standard Time, karls@... writes: re: However, I have not been able to get any follow-up on what the trial's demonstrated. This does not encourage participation in clinical trials. Amen! Pat. A notable quote on this subject: "... the practice of publishing only some results, but not others,3,4 undermines our collective ability to make rational decisions about medical care. ... Ethical clinical research should contribute to generalizable knowledge and improve human health. **** The dedication of patients who take the risks to participate in clinical research is dishonored when their data remain secret. " SPECIAL REPORT: Progress and Deficiencies in Clinical Trial Reporting http://bit.ly/a9ffVv ==However, I have not been able to get any follow-up on what the trial's demonstrated. This does not encourage participation in clinical trials. > > Pat> age 53, > dx 11/04; Rituxan monotherapy 9/05-11/07> clonal evolution to 11q del; unmutated> FCR+Lumi 12/07 - 3/08 5 of 6 cycles - CR> Quote
Guest guest Posted February 12, 2010 Report Posted February 12, 2010 Hi , When it comes to investigational single agents, termination is a marketing decision - a board room decision based on whether it is likely to be profitable in the long term, if testing can be financed, the early results (good and bad) and the assessment of competing products. But I think there's an ethical issue here. When a commercial activity involves human subjects, a full report of events (good and bad) should be mandatory. Karl > > This is a critical issue - lets please have more facts - the trial was > conducted, the patient achieved a CR, and now we have doubts? The lack of > information, if that is indeed the case, could be alarming. Could some of you > guys who know more about this please post? Thanks, > > > In a message dated 2/12/2010 12:39:57 P.M. Eastern Standard Time, > karls@... writes: > > > > > re: However, I have not been able to get any follow-up on what the trial's > demonstrated. This does not encourage participation in clinical trials. > > Amen! Pat. A notable quote on this subject: > > " ... the practice of publishing only some results, but not others,3,4 > undermines our collective ability to make rational decisions about medical > care. ... Ethical clinical research should contribute to generalizable > knowledge and improve human health. > > **** The dedication of patients who take the risks to participate in > clinical research is dishonored when their data remain secret. " > > SPECIAL REPORT: Progress and Deficiencies in Clinical Trial Reporting > _http://bit.ly/http:/_ (http://bit.ly/a9ffVv) > > == > > However, I have not been able to get any follow-up on what the trial's > demonstrated. This does not encourage participation in clinical trials. > > > > Pat > > age 53, > > dx 11/04; Rituxan monotherapy 9/05-11/07 > > clonal evolution to 11q del; unmutated > > FCR+Lumi 12/07 - 3/08 5 of 6 cycles - CR > > > Quote
Guest guest Posted February 13, 2010 Report Posted February 13, 2010 Dr. Furman, Thank you for your wisdom. Norma Oxley dx 12/05; tx 2/06-3/06 w/6 infusions of Rituxan. I have been fine since 3/31/06. Quote
Guest guest Posted February 13, 2010 Report Posted February 13, 2010 I think there are also several different issues being confused here. There is a definite need for all clinical trials to be registered with the National Cancer Institute or National Institutes of Health. There should also be a mandatory reporting of all trial results. This last part is the most important in order to guarantee negative results are not buried by pharmaceutical companies or researchers. The greatest concern for all researchers, physicians, and patients is not having all of the facts when deciding treatment options. There is a long history of negative trials not being published or reported. A negative trial could have as great an impact upon treatment decisions as a positive trial. A separate issue that some have been mentioning is the reporting of results of trials before they are mature. This should not be done. Trials results, and thus conclusions, can change when results are prematurely published. All clinical trials have a target number that is arrived at based upon statistics to ensure that a trials response rate, duraion, etc. are statistically valid. An example would be a trial done where the first 10 patients might all respond, but the next 10 do not. The response rate goes from 100% to 50%. While this is unlikely to happen in a well run trial, we do see biases when one trial site opens first and puts many patients on, and then when the trial opens elsewhere, the newer sites have different selection biases and lower response rates. Likewise, many remember Genasense. Genasense reported their data at the 36 month mark, which showed an improvement in responses, but not survival, so the FDA declined to approve it. Now with data at the 60 month mark, there is a survival advantage. For these reasons, trial results should only be reported when mature, which is determined by statistical guidelines that have been vetted. Rick Furman, MD > > I just read a brief earnings article on Biogen in the Wall St Journal which mentioned that the Company had discontinued its trial of the anti-CD 23 drug, Lumiliximab last October. Has anyone heard anything about this or have any information on what the trial results looked like? I participated in the Phase II/III trial of FCR+Lumi with Dr. Byrd at OSU from 12/07 - 3/08. It was a major expense personally to travel from Baltimore to OSU to participate in the trial and thank goodness I have very comprehensive insurance, as almost none of the expense was covered by the trial. For me personally, I was in the arm that received Lumi and I achieved a CR. However, I have not been able to get any follow-up on what the trial's demonstrated. This does not encourage participation in clinical trials. > > Pat > age 53, > dx 11/04; Rituxan monotherapy 9/05-11/07 > clonal evolution to 11q del; unmutated > FCR+Lumi 12/07 - 3/08 5 of 6 cycles - CR > Quote
Guest guest Posted February 13, 2010 Report Posted February 13, 2010 Thank you. Interim reporting seems a common event at ASH / ASCO? What do you suppose are the reasons? Is this sometimes done to encourage investment? I think it worth noting that publishing early allows the sponsor/investigators to cherry pick the most positive results along the continuum ... so we should take the chosen snapshot with a grain of salt. I suppose enthusiasm for the project could be a motivation, a desire to show and share what is being done, abetted by the frustration of slow enrollment? On the other hand it gives patients at least some basis for deciding on which trials to consider. Karl > > > > I just read a brief earnings article on Biogen in the Wall St Journal which mentioned that the Company had discontinued its trial of the anti-CD 23 drug, Lumiliximab last October. Has anyone heard anything about this or have any information on what the trial results looked like? I participated in the Phase II/III trial of FCR+Lumi with Dr. Byrd at OSU from 12/07 - 3/08. It was a major expense personally to travel from Baltimore to OSU to participate in the trial and thank goodness I have very comprehensive insurance, as almost none of the expense was covered by the trial. For me personally, I was in the arm that received Lumi and I achieved a CR. However, I have not been able to get any follow-up on what the trial's demonstrated. This does not encourage participation in clinical trials. > > > > Pat > > age 53, > > dx 11/04; Rituxan monotherapy 9/05-11/07 > > clonal evolution to 11q del; unmutated > > FCR+Lumi 12/07 - 3/08 5 of 6 cycles - CR > > > Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.